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Abstract 
Chronic kidney disease (CKD) is a heterogeneous range of disorders affecting up to 11% of the 
world’s population. The majority of patients with CKD die of cardiovascular disease (CVD) prior to 
progressing to end stage renal disease (ESRD). 
CKD patients have an increased risk of atherosclerotic disease as well as a unique cardiovascular 
phenotype. There remains no clear aetiology for these issues and a better understanding of the 
psychopathology of CKD associated CVD is urgently needed.  
Although non-animal studies can provide insights into the nature of disease, the whole-organism 
nature of CKD-associated CVD means that high quality animal models, at least for the immediate 
future, are likely to remain a key tool in improving our understanding in this area.  
We will discuss the methods used to induce renal impairment in rodents and the methods available 
to assess cardiovascular phenotype and in each case describe the applicability to humans. 
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Article 
Chronic kidney disease (CKD) is the term given to a heterogeneous range of disorders affecting the 
structure and function of the kidney. It is a global health problem, affecting up to anywhere between 
9%-11% of the world’s population [1]. It is driven by a broad range of aetiologies and can progress to 
end-stage renal disease (ESRD), a condition which can only be treated by dialysis or renal 
transplantation.  However, populations with CKD, pose a substantial healthcare burden aside from 
provision of renal replacement therapy, mainly attributable to cardiovascular (CV) morbidity and 
mortality. Indeed the majority of patients with CKD will die from cardiovascular disease (CVD) prior 
to progressing to ESRD [2].  
Compared to the general population patients with CKD have a higher burden of traditional CVD risk 
factors. These in turn behave in a more accelerated fashion, for example, CKD patients have more 
severe coronary artery atherosclerotic plaque formation compared to the general population [3,4] 
and the risk of myocardial infarction among CKD patients is twice that of patients without CKD [5]. 
Similarly, peripheral artery disease [6] and stroke [7] all show increased risk as the estimated 
glomerular filtration rate beings to fall below 60ml/min per1.73m2.  
Alongside increased risks of atherosclerotic disease CKD also leads to a distinctive cardiovascular 
phenotype characterised by prominent endothelial dysfunction, arterial stiffening and calcification 
alongside left ventricular hypertrophy, fibrosis and cardiac dysrhythmia. CKD-associated CVD 
typically leads to clinical outcomes such as admission for heart failure and sudden cardiac death. It is 
these clinical events that constitute the leading causes of morbidity and mortality in patients 
receiving dialysis [8]. Although a number of underlying risk factors and mechanisms for this clinical 
syndrome have been described including proteinuria [9], anaemia[10], salt retention [11], retention 
of uraemic toxins [12], inflammation [13] and oxidative stress [14] there remains no clear 
aetiological framework for these problems. A better understanding of the pathophysiology of CKD-
associated CVD is therefore urgently required, both to better understand the nature of the risk, and 
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to develop novel therapies aimed at reducing the burden of CVD in this population. Although 
epidemiological, clinical translational and in vitro studies can provide insights into the nature of 
disease, the whole-organism nature of CVD-associated CVD means that high quality animal models, 
at least for the immediate future, are likely to remain a key tool in improving our understanding in 
this area.  
Most scientists aspire to a future where use of cell-based systems and cross-platform bioinformatics 
approaches make animal experimentation redundant but currently rodent disease models provide a 
unique insight into whole organism physiology and pathophysiology.  However whilst animal models 
of disease remain necessary all studies should be designed to minimise suffering and in accordance 
with the “Three R’s”. That is, “Replacement” of animals with other methods if possible, 
“Refinement” of animal models to maximise data gained per animal and “Reduction” of animals 
used where possible [15].  
There is a long history of modelling chronic renal injury in rodents[16]. These models can be used to: 
(i) simulate specific diseases that cause CKD, for example diabetes [17] or systemic lupus 
erythematous [18]; (ii) examine the final common fibrosis pathways of progressive CKD; or (iii) to 
investigate CKD complications such as CKD associated CVD. It is this third aim that will be the focus 
of this review. 
Although atherosclerotic disease and the consequences of athero-occlusive events have been 
modelled in animals in the context of renal injury (e.g. ApoE KO [19] or coronary artery occlusion in 
rat models [20]), we focus on models aimed at investigating the distinctive cardiovascular phenotype 
of CKD associated CVD in this review. We will discuss the methods used to induce renal impairment 
in rodents (Table 1) and the methods available to assess cardiovascular phenotype (Table 2) and in 
each case describe the applicability to humans.  
Rodent Models of CKD 
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Unilateral ureteric obstruction (UUO): The UUO model has been performed in rats and mice. One 
ureter is tied off causing increased urinary tract pressure proximal to the lesion followed by an 
interstitial inflammatory response with subsequent cellular invasion and eventual tubulointerstitial 
fibrosis and atrophy.  The degree of fibrosis is proportional to the length of time the ureter is tied off 
[21]. In general the contralateral kidney, which in situ, provides a control “normal” kidney to be 
analysed histologically alongside the obstructed one. The advantage of this model is that it is 
technically less challenging than nephrectomy, it is easily reproducible and works in most strains of 
both mice and rats. The renal damage occurs rapidly, reaching peak within 7 days. However, whilst 
human CKD can be caused by urinary obstruction [22], overall it is not a major cause of CKD in the 
adult population, and even when it is, partial rather than complete obstruction is typical [23]. 
Furthermore in rodent models, the remaining functioning kidney also goes onto compensate for loss 
of function of the obstructed kidney. Thus, biomarkers of renal failure, such are serum urea and 
creatinine or proteinuria are often not clearly elevated using this model. Efforts to better reflect 
human disease, for example partial or reversible obstruction have been explored [24], but are not in 
widespread use due to their surgical difficulty therefore limiting the utility of this type of model.  
Surgical nephron reduction: Sub-total nephrectomy mimics the consequences of reducing functional 
renal mass. It is most often used in rats and encompasses two different methodologies. The first is a 
ligation model where one kidney is removed with consequent ligation of polar branches of the renal 
artery of the contralateral kidney. In the other method, the rat undergoes a nephrectomy and then 
roughly 50% of contralateral kidney is excised 1-2 weeks later. The latter model does not tend to 
manifest with hypertension whilst the former does [25]. In both models the rats develop progressive 
renal failure by week 2 with renal histology showing progressive glomerular and interstitial fibrosis 
with renal dysfunction and proteinuria which is similar to that found in human disease [26]. 
Conversely mice are typically resistant to induction of chronic renal injury by nephron reduction[27] 
although there is substantial inter-strain variability [28]. Furthermore the challenges of carrying out 
surgery in small animals should not be underestimated [29]. 
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Uninephrectomy DOCA/salt models: The mineralocorticoid deoxycorticosterone acetate (DOCA) 
when administered with a high salt diet and unilateral nephrectomy induces renal injury, low renin 
levels and hypertension in both rat and mouse models. It consists of a 2-6-week period of high salt 
and mineralocorticoid exposure. The DOCA itself is administered by either subcutaneous pellet 
insertion or oral supplementation. Animals then develop hypertension followed by proteinuria, 
glomerular sclerosis, tubulointerstitial inflammation and fibrosis in keeping with progressive CKD 
[30] although the severity of the phenotype varies between different rodent strains. For example, 
129/SV mice have markedly higher DOCA-induced blood pressure, glomerulosclerosis, interstitial 
fibrosis and albuminuria compared to C57BL/6 mice [31]. 
This model has been used to investigate the relationship between the renin–angiotensin–
aldosterone system (RAAS) activation and CKD [32] as well as the therapeutic effect of angiotensin 
converting enzyme inhibitors (ACE-I)  [33]. The cardiovascular phenotype probably reflects only one 
of the potential mechanisms (i.e. sodium retention ± oxidative stress) through which kidney injury 
impacts on the CV system. Therefore, although this approach has been used extensively to study 
hypertension and the final common pathway of CKD it may not provide a comprehensive model for 
interrogating the fundamental mechanisms of CKD-associated CVD. 
Nephrotoxic Models of CKD: Nephrotoxic models of CKD are attractive as they typically cause less 
suffering and are technically less challenging than surgical models. First proposed as a viable CKD 
model in 1982 [34], adenine, when administered in high quantities, saturates the adenine 
phosphoribosyl transferase pathway, causing it to be oxidised into 2,8 dihydroxyadenine by xanthine 
oxidase. 2,8-dihydroxyadenine is renally excreted and precipitates within the tubule leading to 
tubulointerstitial inflammation and fibrosis [35]. The adenine model leads to severe CKD, with 
marked biochemical renal failure and associated vascular calcification [36]. By adjusting the 
concentration of adenine in rat chow Shobeiri et al. were able to produce stable CKD at 5, 8 and 11 
weeks [36]. Sex plays a key role in this model with female rats requiring higher adenine 
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concentrations in their diet to achieve the same severity of kidney injury [37]. The model has also 
been validated in mice [38]. Hypophosphatemia, secondary hyperparathyroidism, renal 
osteodystrophy and vascular calcification are prominent in this model [39], a phenotype consistent 
with the consequences of the CKD-mineral bone disorder (CKD-MB) observed in patients.  
A single dose of 250mg/kg of folic acid causes an acute kidney injury in mice. Animals go onto form 
crystals within the tubular lumen causing acute tubular damage followed by tubulointerstitial 
fibrosis over 2 weeks [40] . By alkalinising the urine, using sodium bicarbonate, folic acid crystals can 
be reduced but tubular damage still occurs suggesting a direct nephrotoxic effect also contributes in 
this model [41]. Acute damage occurs within 2 weeks with the chronic fibrosis becoming apparent 
between 4-6 weeks. Biochemical markers of renal impairment occur in parallel with renal fibrosis 
[42] making this a particularly useful model for studying the consequences of CKD of different 
severity.  This model is increasingly used, for example Rattanasinganchan et al. used this approach to 
investigate urinary biomarkers of tubulointerstitial fibrosis [43]  
Aristolochia when given to animals(rats at a dose of 10 mg/kg daily subcutaneous injections for 35 
days, for mice 3mg/Kg intraperitoneally every 3 days for 6 weeks) induces proteinuria, elevated 
serum creatinine with associated tubular necrosis, atrophy and interstitial fibrosis by day 35 [44,45]. 
These findings closely resemble those found in Chinese-herb nephropathy in humans a disease in 
which aristolochia has been shown to be the causative agent [46]. As such this model of human 
tubulointerstitial nephritis and has been predominantly used to study the molecular basis of kidney 
fibrosis rather than to investigate CKD-associated complications. However, given that albuminuria is 
a feature of this model, some studies have suggested that aristolochia may also lead to  glomerular 
damage with podocyte effacement noted on electron microscopy [47]. This model has 
predominantly been investigated in mice (NMRI, FVB, C76BL/6, C3H/He strains have all been 
studied) and there is some evidence that there may be a degree of renal recovery after 9- 15 weeks 
[45].  
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Immunological models: Of the immunological models, the anti-thy1 model in rats has been most 
studied. Thy-1 is an antigen found on glomerular mesangial cells. When rats are injected with a 
single dose of either anti-thymocyte serum (containing anti-Thy1 antibodies) or a mouse anti-Thy1 
monoclonal antibody, animals develop a glomerulonephritis [48]. Histologically there is initially 
mesangiolysis with an inflammatory cell infiltrate followed by mesangial matrix expansion with the 
occasional extracellular crescent [49]. This process takes roughly 1 week with subsequent repair 
from 3 weeks onwards. The renal phenotype of proteinuria, haematuria and renal impairment 
reflects the abnormalities seen in human glomerulonephritis (GN). Although in humans there is 
hypertension (as opposed to normotension in animals) and immune complex deposits histologically, 
that are not seen in the animal model. This model has also been combined with uninephrectomy to 
produce a GN model more typical of a glomerulonephritis associated CKD [50]. Note this model is 
not viable in mice.  
Other models: We have only outlined the most commonly used approaches to induce renal injury in 
rodents.  Many others are described, particularly those aimed at modelling specific diseases, these 
include: Spontaneous models of glomerular and interstitial injury such as NZB/W lupus nephritis 
model [51], or the Sprague Dawley rat aging model [52], spontaneously hypertensive rats (SHR) [53]; 
genetically engineered models such as the mouse Alports model lacking collagen alpha 3(IV)  [54]; 
acquired immunological models such as  models of anti-glomerular basement disease (anti-
GBM)[55]; acquired non-immunological models such as radiation nephropathy [56] or cyclosporine 
nephropathy [57]. These approaches have been extensively reviewed elsewhere [16].  
 
Cardiovascular phenotyping 
Blood pressure is the simplest cardiovascular phenotype and is typically elevated in CKD. Non-
invasive methods involve using a tail-cuff.  This can be performed on awake restrained rodents. 
However, restraint induces agitation in mice and rats unless they have been suitably conditioned and 
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tail-cuff readings generally correlate poorly with invasive measures [58]. Terminal invasive methods 
require the use of anaesthetic agents that may interfere with BP readings [59].  Conversely 
telemetry devices allow BP measurement during normal activity [60] and represent the gold-
standard approach, however, this requires additional animal procedures, the surgery is technically 
challenging and equipment expensive. Blood pressure measurements have typically been performed 
in all the models described above. Hypertension is typically observed in the nephron reduction, 
DOCA-salt, folic acid and the adenine models, however, there are marked differences between 
species and strains [61].  
Pulse wave velocity (PWV) using ultrasound non-invasively or invasively directly relates to the 
burden of atherosclerotic disease in both animals [62] and humans [63]. However it is also a key 
measure of arterial stiffness in the absence of atherosclerosis and therefore an important 
characteristic of CKD associated CVD. PWV is quantified in animals by measuring two pressures a 
known distant apart with high fidelity transducers and then determining the delay between 
waveforms. The adenine model exhibits increased PWV, this occurs early within 5 days of model 
induction [64] and continues as the animals vasculature becomes more calcified [65].  
Abnormal endothelial function has long been linked to the pathophysiology of CKD associated CVD 
with a number of implicated mechanisms including alterations in nitric oxide (NO), asymmetric 
dimethylarginine (ADMA) and advanced glycation end products (AGEs) [66]. Hypertension is known 
to cause endothelial dysfunction and in nephrectomy rat models [67] and DOCA-salt models 
aberrant levels of endothelial mediators are found [68]. However, the folic acid [69], adenine  
[70,71] and UUO [72] models have all been used to investigate mechanisms and potential 
therapeutics of endothelial dysfunction in CKD. Most simply these methods are ex vivo 
transcriptomic assays however, there have been some attempts to model in vivo endothelial 
function using high-resolution ultrasound to measure flow-mediated vasodilation in both rats and 
mice in response to different endothelial activators or inhibitors [73,74].  
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Arterial histology in CKD associated CVD typically demonstrates medial thickening or fibrosis along 
with calcification in the smooth muscle layer and this phenotype has been demonstrated in animal 
models.  Initially the adenine model involved feeding the animals a high phosphate diet that 
drastically reduced the animals’ weight and confounded results, however, an updated model 
involving a high initial adenine dose combined with a normal diet has resolved this issue [75]. 
However, in non-adenine models combining a high phosphate diet with the existing model can 
heighten the calcific phenotype [36]. Histopathology can also demonstrate accelerated plaque 
formation when examining models of atherosclerotic disease in the context of chronic renal injury.  
Functional cardiac imaging is also possible in small animals. Patients with CKD-associated CVD 
typically demonstrate LVH, ventricular dysfunction and cardiac fibrosis. Teams such as Zhang et al 
[26] have utilised echocardiography to analyse systolic and diastolic functioning of the hearts in 
animal models of renal injury; revealing impairment in both. Cardiac MRI has also been used to 
illustrate cardiac hypertrophy and fibrosis in rodent models of CKD [76].  
Others have demonstrated ex vivo functional changes for example, decreased contractility in a sub-
total nephrectomy model in rats [77].  Cardiac histology (and weight) can also be used to 
demonstrate increased heart size and fibrosis. For example, the DOCA-salt model (rats and mice) 
also exhibit a cardiac phenotype in keeping with hypertension with increased heart size, cardiac 
fibrosis [68]. 
To what degree the above animal models of chronic kidney injury recapitulate the CV phenotype, 
other than hypertension and LVH, observed in patients has been inadequately explored in all but a 
few cases. However some of the above models do demonstrate vascular features suggestive of some 
aspects of arterial disease seen in CKD and are worth additional comment.  
For example, the adenine model, alongside hypertension, mimics the CKD-MBD with evidence of 
arterial calcification and hyperphosphatemia and secondary hyperparathyroidism. Evidence from 
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this model suggests vascular smooth muscle cells transform into an osteochondrogenic-like 
phenotype  [78–80].   
Reduced NO bioavailability has long been suggested to underlie vascular pathology in CKD. Rats that 
have undergone subtotal nephrectomy, develop a worsening systolic function and cardiac fibrosis 
(both features of CVD-associated CKD) when treated with a low dose of a NO synthase inhibitor, 
providing support to this theory [81] . Similarly a nephrectomy rat model has been used to highlight 
the role of the uraemic toxin indoxyl sulfate in cardiac fibrosis, as well as test out monoclonal 
antibodies again cardiotonic steroids implicated in uraemic cardiomyopathy [82,83].  
 
Therefore the evidence for mechanisms underlying the kidney-vascular link remain sparse and 
certainly there is no comprehensive understanding of the pathological pathways leading to the 
development of CKD associated CVD. This will not only require induction of a range of different 
models of CKD but the systematic characterisation of CV phenotype using whole organism 
physiological measures, imaging and interrogation of isolated tissues, across multiple time points.  
 
General considerations designing experiments based on animal models of CKD associated CVD  
A number of further considerations arise when planning experiments based on animal models of 
CKD-associated CVD, both general and specific to the research question. The generalizability of the 
model given the age, sex, species, and strain of the animals included in the experiment is 
fundamental to the conclusions being drawn. For example although experiments are typically 
performed in mice at age 8-12 weeks old, older animals [84] are likely to better reflect the 
pathophysiology observed in human CKD, a disease of middle and old age [85]. Similarly the sex of 
animals has been shown to influence the phenotype of models across a wide range of organ systems 
[86].  
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Species and strain is also important. Whilst mouse models are becoming more popular than rats due 
to the ability for genetic manipulation [87] and lower cost, many of the CKD models rely on surgical 
procedures and CV measurements which are technically less challenging in larger animals such as 
rats. Furthermore several strains of mice seem uniquely resistant to developing disease phenotype 
in several of the models described above (see Table 1). In addition rats used in experiments are 
typically outbred thus standardised nomenclature describing each strain e.g. “Wistar”, may be 
misleading as there can be a great deal of genetic heterogeneity within these broad strain 
descriptions [88]. 
Focusing on models of CKD associated CVD it is important to ensure that key CV findings are not 
related to the method of inducing kidney injury in the animal. Hence any proposed pathway or 
intervention should be examined in at least two differing models of CKD, e.g. one surgical and 
nephrotoxic model, and ideally across both rats and mice. Similarly the heterogeneity of human CKD 
must be recognised, again implying any important findings are replicated across surgical, toxic and 
immunologically induced models of renal injury. Finally the complexity of some of the procedures, 
particularly those related to CV phenotyping, means that only teams with extensive experience of 
performing this type of work can achieve high levels of reproducibility and minimise adverse events 
for experimental animals. To ensure compliance with the “three Rs” investigators without 
appropriate skills should ensure they collaborate with those that do. 
Conclusion 
Although advances in technology may mean this approach becomes redundant, animal models will 
likely continue to be a useful method to describe pathophysiology and test potential therapies in 
CKD related CVD for decades to come. Thoughtful design of experiments, replication using different 
models and in-depth phenotyping using a wide range of techniques mean that we can maximise the 
benefits from these studies and over the longer term produce real benefit for patients.  
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 Table 1 CKD phenotyping in animal models   
Model Method of 
Injury  
Species Strain Sex 
differences 
Time 
course 
Renal Histological 
findings in animal 
Translation to 
human disease 
Other 
considerations 
References 
5/6 
nephrectomy 
Renal mass 
reduction 
Rat/Mouse Multiple Males 
more 
susceptible  
0-12 
weeks 
Glomerulosclerosis, 
mesangial 
expansion, 
tubulointerstitial 
fibrosis 
Model for 
hyperfiltration 
injury e.g. renal 
cancer 
nephrectomy 
patients  
Mice (esp 
C57BK/6) 
highly 
resistant 
Surgically 
complex 
Removed 
kidney is good 
control 
[25–27] 
Adenine Tubular injury Rat/Mouse Multiple Males 
more 
susceptible 
6 weeks Tubulointerstitial 
fibrosis, vascular 
calcification 
Mimics CKD-MBD  Simple 
Rapidly 
progressive 
[34,35,37–
39] 
Aristolochia Tubular injury  Rat/Mouse Multiple None 
known 
1-6 weeks 
post-dose 
Tubulointerstitial 
fibrosis, potentially 
some podocyte 
damage 
Aristolochia 
nephropathy 
Simple 
Toxic 
nephropathy 
rare cause of 
CKD in 
humans 
[44,45,47] 
Folic Acid Tubular injury Rat/Mouse Multiple None 
known 
1-6 weeks 
post-dose 
Tubulointerstitial 
fibrosis, potentially 
some podocyte 
damage 
Cyclosporine 
induced interstitial 
nephritis 
Toxic 
nephropathy 
rare cause of 
CKD in 
humans 
[40–42] 
DOCA-salt Renal mass 
reduction , 
vasoconstriction, 
hypertension 
Rat/Mouse Multiple 
rat, C57 
mice 
More 
severe in 
males 
4 weeks Glomerulosclerosis Hypertensive CKD 
 
 
Proteinuria, 
hypertension, 
low renin 
[30–33] 
Anti-Thy1 Immune-
mediated injury 
Rat/Mouse Multiple None  
Known  
Immediate 
to 3 weeks 
Mesangial 
necrolysis, 
mesangial 
General model of 
glomerulonephritis 
with a 
Needs 
nephrectomy 
to produce 
[48–50] 
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expansion, 
occasional 
crescents 
predominant 
mesangial 
component 
longer term 
phenotype 
UUO Ligation of single 
ureter 
Rat/Mouse Multiple None 
known 
0-2 weeks Hydroneprhosis, 
tubulointerstitial 
fibrosis  
Ureteric 
obstruction not 
common cause of 
CKD 
No change in 
functional 
readouts 
Allows for 
internal 
control 
[21,22,24] 
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Table 2 CV phenotyping in animal models  
 
Clinical CV 
phenotype 
Measure in 
animals  
Advantages  Disadvantages  References  
Blood pressure NIBP Simple  
 
Not 
Reproducible 
Complicated by 
anaesthetic  
[58–61] 
Terminal IBP Simple Sacrifices 
animal  
Telemetry  Reliable and 
continuous  
Surgery 
required 
Arterial stiffening 
and calcification 
PWV Can be done non-
invasively  
 
Cannot 
differentiate 
atherosclerotic 
disease from 
medial fibrosis 
and calcification 
[36,62–64] 
Endothelial 
function 
Allows for mechanistic 
approach to CKD-CVD 
Whilst plays a 
part in human 
disease – not 
routinely 
measured in 
clinic practice  
[67,68,74] 
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Histology / 
transcriptomics 
Allows for mechanism 
discovery  
 [68] 
Atherosclerotic 
disease 
Endothelial 
function  
As above  As above As above 
Histology  Better understanding 
of underlying 
pathophysiology  
 [36,75] 
LVH Heart weight  Simple Coarse 
measurement  
[68] 
In vivo imaging Functional read-outs, 
more physiological. 
Read-outs can easily 
compare to human 
clinical practice  
Technically 
challenging 
[26,76] 
Heart failure In vivo imaging As above  As above  As above 
Ex-vivo 
functional 
studies 
Allows for easy 
variation of 
environment with 
functional readouts 
Can only 
partially 
recreate true 
internal 
physiology  
[77] 
Histology Allows for 
investigation of final 
common-pathway  
Sacrifice of 
animal 
As above 
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